How the Cdc34 protein helps control cell division
Structure and Function of the Essential Cell Cycle Regulator Cdc34
Researchers are looking at how the Cdc34 protein's shape and actions control protein breakdown and cell division, which matters for cancers tied to these systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11295420 on NIH RePORTER |
What this research studies
You will read about lab research that maps the three-dimensional shape of the Cdc34 protein and tests how it binds partners that tag proteins for destruction. The team uses structural methods and biochemical and cell-based experiments to see how specific parts of Cdc34 drive ubiquitin chain formation. They will also test how changes in Cdc34 activity affect proteins that control the cell cycle. The goal is to explain molecular steps that, when faulty, can contribute to cancer.
Who could benefit from this research
Good fit: People with cancers known to involve protein degradation pathways (for example some leukemias or multiple myeloma) or those willing to provide tissue or blood samples for lab studies may be relevant to this research.
Not a fit: Patients whose conditions are unrelated to ubiquitin/proteasome biology are unlikely to see a direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets for drugs that interfere with cancer cells' ability to control protein breakdown.
How similar studies have performed: Drugs that target the broader ubiquitin–proteasome system have helped some cancers, but directly targeting Cdc34 is a newer and less-tested approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Olsen, Shaun — University of Texas Hlth Science Center
- Study coordinator: Olsen, Shaun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.